<DOC>
	<DOCNO>NCT00440154</DOCNO>
	<brief_summary>The primary objective study assess effect AVE5530 LDL-C level period 4 week . The secondary objective assess effect AVE5530 lipid plasma level safety tolerability AVE5530 .</brief_summary>
	<brief_title>A Study Evaluating Safety Efficacy AVE5530 ( 4 Weeks ) Patients With Mild Moderate Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Patients mild moderate primary hypercholesterolemia stabilize LDLC baseline ≥130 mg/dL ≤ 250 mg/dL ( ≥ 3.36 mmol/L ≤ 6.46 mmol/L ) Male age ≥ 18 year postmenopausal woman screen Presence clinically significant endocrine disease know influence serum lipid lipoproteins Patients type 1 diabetes Presence history cancer within past five year Triglycerides ≥ 300 mg/dL ( 3.39 mmol/L ) Fasting plasma glucose &gt; 160 mg/dL ( 8.9 mmol/L ) Impaired kidney function active liver disease Within one month prior screen visit and/or time screen visit , administration lipid lower treatment Creatine Kinase &gt; 2xUpper Limit Normal range The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>